Karolinska Development names Christian Tange to succeed Robin Wright

28 January 2014

Karolinska Development has announced that Christian Tange has accepted the role of Chief Financial Officer. He will succeed Robin Wright, who will be leaving the company at the end of February, following the audit and report of the 2013 annual results.

Mr Tange has more than 15 years’ experience in international growth companies. In recent years, he has acted as an industrial advisor and consultant for Private Equity funds and Corporate Finance advisors in M&A deals within life science. During the period 2003-2012 he worked as global CFO of CMC Biologics, an international biotech contract manufacturing company. Christian holds a Master’s degree in Economics and Law from Copenhagen Business School. He will start working with Karolinska Development from February 1 and take on the CFO role on March 1.

Torbjörn Bjerke, chief executive of Karolinska Development, said: “After many years of working in Sweden, Robin Wright has decided to leave Karolinska Development to take up a new role in the UK to be nearer to his family. We understand and respect his decision and we thank him for his significant contributions to the company’s progress. At the same time, it is a pleasure to welcome Christian Tange to the CFO position. Christian has a strong track record as CFO and his experience in healthcare M&A and business development matches perfectly with Karolinska Development’s current focus. I am looking forward to working with him in future deals.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical